New Approaches to Targeting B Cells for Myasthenia Gravis Therapy.

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10780
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 10 Firefox

New Approaches to Targeting B Cells for Myasthenia Gravis Therapy.

Message par Pboulanger Prés. »

:hi:
:arrow:

Lu sur : https://www.ncbi.nlm.nih.gov/pubmed/32153573
 Nouvelles approches pour cibler les cellules B pour la thérapie de la myasthénie grave.


 
[hr]
[/hr]

Traduction disponible directement en cliquant en bas a droite de ce message sur l'expression Traduire en

Image
[hr]
[/hr]
Titre de l'article New Approaches to Targeting B Cells for Myasthenia Gravis Therapy.
Date de l'article Front Immunol. 2020 Feb 21;11:240. doi: 10.3389/fimmu.2020.00240. eCollection 2020.

Contenu de l'article

Current therapies for myasthenia gravis (MG) are limited, and many investigations have recently focused on target-specific therapies.

B cell-targeting monoclonal antibody (mAb) therapies for MG are increasingly attractive due to their specificity and efficacy.

The targeted B cell biomarkers are mainly the cluster of differentiation (CD) proteins that mediate maturation, differentiation, or survival of pathogenic B cells.

Additional B cell-directed therapies include non-specific peptide inhibitors that preferentially target specific B cell subsets.

The primary goals of such therapies are to intercept autoantibodies and prevent the generation of an inflammatory response that contributes to the pathogenesis of MG.


Treatment of patients with MG using B cell-directed mAbs, antibody fragments, or selective inhibitors have exhibited moderate to high efficacy in early studies, and some of these therapies appear to be highly promising for further drug development.

Numerous other biologics targeting various B cell surface molecules have been approved for the treatment of other conditions or are either in clinical trials or preclinical development stages.

These approaches remain to be tested in patients with MG or animal models of the disease.

This review article provides an overview of B cell-targeted treatments for MG, including those already available and those still in preclinical and clinical development.

We also discuss the potential benefits as well as the shortcomings of these approaches to development of new therapies for MG and future directions in the field.


 
[hr]
[/hr]

Message d' un membre de l'équipe technique
Pour les utilisateurs d'I-phone
ci-dessous le lien vers Google Trad

https://translate.google.fr/translate?h ... 2F32153573
Message d' un membre de l'équipe technique
Nous utilisons des services automatiques de traduction fournis
par Yandex ou Google.
Soyez vigilant sur le risque de contre-sens en utilisant ce genre d'outils.
 
[hr]
[hr]
[/hr]


Sur demande de nos donateurs, nous pouvons faire l'acquisition d'un tiré-à-part de l'article intégral
Le coût de est pris en charge par l'Association

 
[hr]
[/hr]


 
Amicalement,
Image
Verrouillé

Retourner vers « 2020 »